SCHEMBL20455902

SCHEMBL20455902

CN1Cc2ccc(C=O)cc2C1=O

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KCNJ1 P48048 1/20 0.51
▸ DDB1 Q16531 2/20 0.45
▸ CRBN Q96SW2 2/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ MEN1 O00255 3/20 0.44
▸ KMT2A Q03164 3/20 0.44
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ PRF1 P14222 1/20 0.40
▸ CYP2A6 P11509 2/20 0.38
▸ ALDH1A3 P47895 3/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.35
▸ HDAC4 P56524 2/20 0.34
▸ HDAC1 Q13547 2/20 0.34
▸ HDAC6 Q9UBN7 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CTSK P43235 1/20 0.34
▸ CTSC P53634 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21873388 0.86 ALDH1A1 (0.47) KCNJ1DDB1CRBNALDH1A1MEN1
SCHEMBL20456055 0.85 GABRA1 (0.44) KCNJ1DDB1CRBNALDH1A1MEN1
SCHEMBL3546902 0.83 MEN1 (0.50) KCNJ1DDB1CRBNALDH1A1MEN1
SCHEMBL21729751 0.83 CNR2 (0.43) KCNJ1DDB1CRBNALDH1A1MEN1
SCHEMBL30514543 0.83 MEN1 (0.50) KCNJ1DDB1CRBNALDH1A1MEN1
SCHEMBL19150822 0.78 KCNJ1 (0.43) KCNJ1ALDH1A1MEN1KMT2AGAA
SCHEMBL435023 0.77 DDB1 (0.48) DDB1CRBNALDH1A1MEN1KMT2A
SCHEMBL21983836 0.75 DDB1 (0.47) DDB1CRBNMEN1KMT2APRF1
SCHEMBL8380361 0.75 DDB1 (0.47) DDB1CRBNALDH1A1MEN1KMT2A
SCHEMBL13213025 0.75 GABRG2 (0.47) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11603349-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD (AU) 2023-03-14 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD (AU) 2021-08-12 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
US-11014873-B2 Anti-fibrotic compounds CERTA THERAPEUTICS PTY LTD. (AU) 2021-05-25 — — US disclosed
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. 2020-02-20 — — US disclosed
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. 2020-02-20 — — US disclosed
CN-110546133-A Anti-fibrotic compounds SHIRE HUMAN GENETIC THERAPIES 2019-12-06 — — CN disclosed
WO-2018144620-A9 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD. (AU) 2019-01-24 — — WO disclosed
WO-2018144620-A9 ANTI-FIBROTIC COMPOUNDS CERTA THERAPEUTICS PTY LTD. (AU) 2019-01-24 — — WO disclosed
WO-2018144620-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2018-08-09 — — WO disclosed
WO-2018144620-A1 ANTI-FIBROTIC COMPOUNDS SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2018-08-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11603349-B2 Anti-fibrotic compounds TGFB1, SMAD3, TGFB2 KCNJ1 4771/4885DDB1 661/4885CRBN 3237/4885
US-20210246100-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, TGFB2 KCNJ1 4771/4885DDB1 661/4885CRBN 3237/4885
US-11014873-B2 Anti-fibrotic compounds TGFB1, SMAD3, SMAD2 KCNJ1 4786/4885DDB1 633/4885CRBN 3169/4885
US-20200055814-A1 ANTI-FIBROTIC COMPOUNDS TGFB1, SMAD3, SMAD2 KCNJ1 4388/4885DDB1 822/4885CRBN 3231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback